Anzeige
Mehr »
Login
Samstag, 26.09.2020 Börsentäglich über 12.000 News von 645 internationalen Medien
Monsterhochzeit - Die 200 Mio. USD News! Kursexplosion am Montag!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 565131 ISIN: DK0010272202 Ticker-Symbol: GE9 
Tradegate
25.09.20
16:24 Uhr
304,40 Euro
+2,50
+0,83 %
1-Jahres-Chart
GENMAB A/S Chart 1 Jahr
5-Tage-Chart
GENMAB A/S 5-Tage-Chart
RealtimeGeldBriefZeit
309,80310,9011:01
309,20311,1025.09.

Aktuelle News zur GENMAB Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
GENMAB Aktie jetzt für 0€ handeln
MiWhy Genmab's Stock Is Trading Lower Today7
MiInSysBio partners with Genmab in solid tumours7
MiGenmab drops 12% on legal dispute with J&J over cancer drug40
MiGenmab shares drop on legal battle with J&J over cancer drug62
DiGENMAB A/S - 6-K, Report of foreign issuer33
DiGenmab A/S: Genmab Commences Binding Arbitration of Two Matters Under License Agreement with Janssen19
MoSeattle Genetics/Genmab antibody-drug conjugate shows positive effect in cervical cancer10
MoSeattle Genetics, Inc.: Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 20202.125- Data Featured in Late-Breaking Proffered Paper Oral Presentation - Biologics License Application Submission Planned to Support Accelerated Approval Pathway with the FDA - Seattle Genetics...
► Artikel lesen
MoGenmab A/S: Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO ...3
10.09.Genmab A/S: Genmab Announces that Janssen has Submitted a Supplemental Biologics License Application to U.S. FDA for use of DARZALEX FASPRO (daratumumab ...7
27.08.Genmab A/S: Genmab Announces Late-Breaking Oral Presentation of Phase 2 innovaTV 204 Study at the ESMO Virtual Congress 20206
20.08.Genmab A/S: Genmab Announces Janssen Granted U.S. FDA Approval for DARZALEX (daratumumab) in Combination with Carfilzomib and Dexamethasone in Relapsed ...11
20.08.Genmab A/S: Genmab Announces Plan to Transition Arzerra (ofatumumab) to an Oncology Access Program for Chronic Lymphocytic Leukemia Patients in the U.S.7
20.08.Genmab A/S: U.S. FDA Approves Kesimpta (ofatumumab) in Relapsing Multiple Sclerosis5
19.08.Nasdaq Copenhagen A/S: Genmab A/S - admittance to trading and official listing of new shares due to employee warrant exercise185The share capital of Genmab A/S has been increased. The admittance to trading and official listing will take effect as per 21 August 2020 in the ISIN below. ISIN: DK0010272202 ...
► Artikel lesen
18.08.GENMAB A/S - 6-K, Report of foreign issuer-
18.08.Genmab A/S: Capital Increase in Genmab as a Result of Employee Warrant Exercise3
13.08.Genmab A/S 2020 Q2 - Results - Earnings Call Presentation20
13.08.Genmab A/S (GMAB) CEO Jan van de Winkel on Q2 2020 Results - Earnings Call Transcript17
12.08.GENMAB A/S - 6-K, Report of foreign issuer4
Seite:  Weiter >>
105 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3